Favipiravir (BioDeep_00000858734)
代谢物信息卡片
Favipiravir
化学式: C5H4FN3O2 (157.0288)
中文名称: 法匹拉韦
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1=C(N=C(C(=O)N1)C(=O)N)F
InChI: InChI=1S/C5H4FN3O2/c6-2-1-8-5(11)3(9-2)4(7)10/h1H,(H2,7,10)(H,8,11)
描述信息
J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals
COVID info from DrugBank, clinicaltrial, clinicaltrials, clinical trial, clinical trials
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents
C471 - Enzyme Inhibitor > C25995 - RNA Polymerase Inhibitor
C254 - Anti-Infective Agent > C281 - Antiviral Agent
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:134722
- KEGGdrug: D09537
- PubChem: 492405
- DrugBank: DB12466
- ChEMBL: CHEMBL221722
- CAS: 259793-96-9
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- T Yang, J Y Zhao, X Wang, Z G Fang, L F Jiang, J Li. [Notch1 inhibits the mechanistic role of STING signaling to regulate hepatocyte lipophagy in nonalcoholic steatohepatitis].
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.
2023 Aug; 31(8):827-834. doi:
10.3760/cma.j.cn501113-20230208-00042. [PMID: 37723064] - Murat Zh Zhurinov, Alfira F Miftakhova, Viktoriya Keyer, Zarina T Shulgau, Elena V Solodova, Maxat K Kalykberdiyev, Arlan Z Abilmagzhanov, Eldar T Talgatov, Sauyk Ait, Alexandr V Shustov. Glycyrrhiza glabra L. Extracts and Other Therapeutics against SARS-CoV-2 in Central Eurasia: Available but Overlooked.
Molecules (Basel, Switzerland).
2023 Aug; 28(16):. doi:
10.3390/molecules28166142. [PMID: 37630394] - Kei Irie. [Pharmacokinetic Study of Antiviral Drugs in Patients with COVID-19].
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.
2023; 143(3):239-241. doi:
10.1248/yakushi.22-00169-1. [PMID: 36858556] - Mangesh Tiwaskar, Raja Dhar, Deepak Talwar, Abdul Ansari, Mahesh Lakhe, Sagar Panchal, Sagar Bhagat, Saiprasad Patil, Hanmant Barkate. Real-world Experience with Favipiravir for Treatment of COVID-19 among Indian Healthcare Professionals.
The Journal of the Association of Physicians of India.
2022 Dec; 69(12):11-12. doi:
NULL. [PMID: 35057588] - Markus Fischer, Peter Müller, Holger A Scheidt, Meike Luck. Drug-Membrane Interactions: Effects of Virus-Specific RNA-Dependent RNA Polymerase Inhibitors Remdesivir and Favipiravir on the Structure of Lipid Bilayers.
Biochemistry.
2022 Jul; 61(13):1392-1403. doi:
10.1021/acs.biochem.2c00042. [PMID: 35731976] - Prajakta Kulkarni, Sriram Padmanabhan. A novel property of hexokinase inhibition by Favipiravir and proposed advantages over Molnupiravir and 2 Deoxy D glucose in treating COVID-19.
Biotechnology letters.
2022 Jul; 44(7):831-843. doi:
10.1007/s10529-022-03259-6. [PMID: 35608787] - Mehdi Hassaniazad, Hossein Farshidi, Abdollah Gharibzadeh, Ali Bazram, Elham Khalili, Afsaneh Noormandi, Mohammad Fathalipour. Efficacy and safety of favipiravir plus interferon-beta versus lopinavir/ritonavir plus interferon-beta in moderately ill patients with COVID-19: A randomized clinical trial.
Journal of medical virology.
2022 Jul; 94(7):3184-3191. doi:
10.1002/jmv.27724. [PMID: 35292989] - Dang The Hung, Suhaib Ghula, Jeza Muhamad Abdul Aziz, Abdelrahman M Makram, Gehad Mohamed Tawfik, Ali Ahmed-Fouad Abozaid, Rohan Andrew Pancharatnam, Amr Mohamed Ibrahim, Muhammad Besher Shabouk, Morgan Turnage, Saloni Nakhare, Zahra Karmally, Basel Kouz, Tran Nhat Le, Suleiman Alhijazeen, Nguyen Quoc Phuong, Alaa Mohamed Ads, Ali Hussein Abdelaal, Nguyen Hai Nam, Tatsuo Iiyama, Kyoshi Kita, Kenji Hirayama, Nguyen Tien Huy. The efficacy and adverse effects of favipiravir on patients with COVID-19: A systematic review and meta-analysis of published clinical trials and observational studies.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
2022 Jul; 120(?):217-227. doi:
10.1016/j.ijid.2022.04.035. [PMID: 35470021] - Won Sriwijitalai, Viroj Wiwanitkit. COVID-19 and favipiravir induce cutaneous adverse reactions: a difficulty in clinical dermatology practice.
Clinical and experimental dermatology.
2022 Jul; 47(7):1382-1383. doi:
10.1111/ced.15202. [PMID: 35357031] - Rezzan Gülhan, Emel Eryüksel, Medine Gülçebi İdriz Oğlu, Yekta Çulpan, Aylin Toplu, Derya Kocakaya, Elif Tigen, Buket Ertürk Şengel, Uluhan Sili, Şehnaz Olgun Yıldızeli, Mehmet Baran Balcan, Abdullah Elçi, Cenk Bulut, Atila Karaalp, Hasan Raci Yananlı, Abdullah Emre Güner, Mustafa Hatipoğlu, Sait Karakurt, Volkan Korten, Neville Ratnaraj, Philip Patsalos, Pınar Ay, Filiz Onat. Pharmacokinetic characterization of favipiravir in patients with COVID-19.
British journal of clinical pharmacology.
2022 07; 88(7):3516-3522. doi:
10.1111/bcp.15227. [PMID: 35014080] - Kimiyasu Shiraki, Noriaki Sato, Kaoru Sakai, Shirou Matsumoto, Richard H Kaszynski, Masaya Takemoto. Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences.
Pharmacology & therapeutics.
2022 07; 235(?):108121. doi:
10.1016/j.pharmthera.2022.108121. [PMID: 35121001] - Adel Ehab Ibrahim, Yasmine Ahmed Sharaf, Sami El Deeb, Rania Adel Sayed. Analytical Performance and Greenness Evaluation of Five Multi-Level Design Models Utilized for Impurity Profiling of Favipiravir, a Promising COVID-19 Antiviral Drug.
Molecules (Basel, Switzerland).
2022 Jun; 27(12):. doi:
10.3390/molecules27123658. [PMID: 35744781] - Mona E El Sharkasy, Manar M Tolba, Fathalla Belal, Mohamed Walash, Rasha Aboshabana. Quantitative analysis of favipiravir and hydroxychloroquine as FDA-approved drugs for treatment of COVID-19 using synchronous spectrofluorimetry: application to pharmaceutical formulations and biological fluids.
Luminescence : the journal of biological and chemical luminescence.
2022 Jun; 37(6):953-964. doi:
10.1002/bio.4240. [PMID: 35343627] - Divya Kumar Vemuri, Rambabu Gundla, Naresh Konduru, Ravindra Mallavarapu, Naresh Kumar Katari. Favipiravir (SARS-CoV-2) degradation impurities: Identification and route of degradation mechanism in the finished solid dosage form using LC/LC-MS method.
Biomedical chromatography : BMC.
2022 Jun; 36(6):e5363. doi:
10.1002/bmc.5363. [PMID: 35292997] - Inas A Abdallah, Sherin F Hammad, Alaa Bedair, Mohamed A Abdelaziz, Neil D Danielson, Ahmed H Elshafeey, Fotouh R Mansour. A gadolinium-based magnetic ionic liquid for supramolecular dispersive liquid-liquid microextraction followed by HPLC/UV for the determination of favipiravir in human plasma.
Biomedical chromatography : BMC.
2022 Jun; 36(6):e5365. doi:
10.1002/bmc.5365. [PMID: 35274347] - Henrietta Papp, Zsófia Lanszki, György M Keserű, Ferenc Jakab. Favipiravir for the treatment of COVID-19 in elderly patients-what do we know after 2 years of COVID-19?.
GeroScience.
2022 Jun; 44(3):1263-1268. doi:
10.1007/s11357-022-00582-8. [PMID: 35543795] - Figen Öztürk Ergür, Murat Yıldız, Melahat Uzel Şener, Suna Kavurgacı, Ayperi Ozturk. Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective study.
Sao Paulo medical journal = Revista paulista de medicina.
2022 May; 140(3):372-377. doi:
10.1590/1516-3180.2021.0489.r1.13082021. [PMID: 35507992] - Md Oliullah Rafi, Gourab Bhattacharje, Khattab Al-Khafaji, Tugba Taskin-Tok, Md Almujaddade Alfasane, Amit Kumar Das, Md Anowar Khasru Parvez, Md Shahedur Rahman. Combination of QSAR, molecular docking, molecular dynamic simulation and MM-PBSA: analogues of lopinavir and favipiravir as potential drug candidates against COVID-19.
Journal of biomolecular structure & dynamics.
2022 05; 40(8):3711-3730. doi:
10.1080/07391102.2020.1850355. [PMID: 33251975] - Yasmine Ahmed Sharaf, Sami El Deeb, Adel Ehab Ibrahim, Ahmed Al-Harrasi, Rania Adel Sayed. Two Green Micellar HPLC and Mathematically Assisted UV Spectroscopic Methods for the Simultaneous Determination of Molnupiravir and Favipiravir as a Novel Combined COVID-19 Antiviral Regimen.
Molecules (Basel, Switzerland).
2022 Apr; 27(7):. doi:
10.3390/molecules27072330. [PMID: 35408729] - Mohammad Bosaeed, Ahmad Alharbi, Ebrahim Mahmoud, Sanaa Alrehily, Mohannad Bahlaq, Zied Gaifer, Hanan Alturkistani, Khaled Alhagan, Saad Alshahrani, Ali Tolbah, Abrar Musattat, Maha Alanazi, Raniah Jaha, Khizra Sultana, Hajar Alqahtani, Kholoud Al Aamer, Saud Jaser, Abdulrahman Alsaedy, Ayoub Ahmad, Mohammed Abalkhail, Sameera AlJohani, Majed Al Jeraisy, Sultan Almaziad, Nahlah Albaalharith, Khaled Alabdulkareem, Abdulmajeed Alshowair, Naif Khalaf Alharbi, Fahad Alrabiah, Majid Alshamrani, Omar Aldibasi, Ahmed Alaskar. Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
2022 Apr; 28(4):602-608. doi:
10.1016/j.cmi.2021.12.026. [PMID: 35026375] - Abbas Al Mutair, Jinan Shamou, Saad Alhumaid, Laila Layqah, Gasmelseed Y Ahmed, Koritala Thoyaja, Mohammed Al Mohaini, Sana Almahmoud, Mazin Barry, Amjad Khan, Kuldeep Dhama, Lamiaa Hamad Al-Jamea, Alxeander Woodman, Ali A Rabaan. Overview of clinical outcome and therapeutic effectiveness of Favipiravir in patients with COVID-19 admitted to intensive care unit, Riyadh, Saudi Arabia.
Journal of infection and public health.
2022 Apr; 15(4):389-394. doi:
10.1016/j.jiph.2022.01.013. [PMID: 35299062] - Yuki Hanai, Sadako Yoshizawa, Kazuhiro Matsuo, Shusuke Uekusa, Taito Miyazaki, Koji Nishimura, Takumi Mabuchi, Hayato Ohashi, Yoshikazu Ishii, Kazuhiro Tateda, Takashi Yoshio, Kenji Nishizawa. Evaluation of risk factors for uric acid elevation in COVID-19 patients treated with favipiravir.
Diagnostic microbiology and infectious disease.
2022 Apr; 102(4):115640. doi:
10.1016/j.diagmicrobio.2022.115640. [PMID: 35193798] - Weishang Deng, Changyuan Yang, Sensen Yang, Haitao Chen, Zhikun Qiu, Jisheng Chen. Evaluation of favipiravir in the treatment of COVID-19 based on the real-world.
Expert review of anti-infective therapy.
2022 Apr; 20(4):555-565. doi:
10.1080/14787210.2022.2012155. [PMID: 34846960] - Abdullah Sayiner, Huseyin Aytac Erdem, Pervin Korkmaz Ekren, Sezai Tasbakan, Ozen K Basoglu, Meltem Isikgoz Tasbakan, Tansu Yamazhan, Deniz Gokengin, Mustafa Hikmet Ozhan. Favipiravir for the treatment of COVID-19 pneumonia: Can we predict the response to treatment?.
Journal of infection in developing countries.
2022 03; 16(3):422-426. doi:
10.3855/jidc.14033. [PMID: 35404846] - Kanako Shinada, Takashi Sato, Saya Moriyama, Yu Adachi, Masahiro Shinoda, Shinichiro Ota, Miwa Morikawa, Masamichi Mineshita, Takayuki Matsumura, Yoshimasa Takahashi, Masaharu Shinkai. Longitudinal Analysis of Neutralizing Potency against SARS-CoV-2 in the Recovered Patients after Treatment with or without Favipiravir.
Viruses.
2022 03; 14(4):. doi:
10.3390/v14040670. [PMID: 35458400] - Manaf AlQahtani, Nitya Kumar, Dhuha Aljawder, Abdulkarim Abdulrahman, Mohammed Wael Mohamed, Fatema Alnashaba, Mohammed Abu Fayyad, Faisal Alshaikh, Fatima Alsahaf, Sawsan Saeed, Amal Almahroos, Zainab Abdulrahim, Sameer Otoom, Stephen L Atkin. Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease.
Scientific reports.
2022 03; 12(1):4925. doi:
10.1038/s41598-022-08794-w. [PMID: 35322077] - Shuang Wang, Chen Wang, Yuxiao Xin, Qiuyun Li, Weilu Liu. Core-shell nanocomposite of flower-like molybdenum disulfide nanospheres and molecularly imprinted polymers for electrochemical detection of anti COVID-19 drug favipiravir in biological samples.
Mikrochimica acta.
2022 03; 189(3):125. doi:
10.1007/s00604-022-05213-9. [PMID: 35229221] - Munetaka Ueda, Tetsuya Tanimoto, Anju Murayama, Akihiko Ozaki, Masahiro Kami. Japan's Drug Regulation During the COVID-19 Pandemic: Lessons From a Case Study of Favipiravir.
Clinical pharmacology and therapeutics.
2022 03; 111(3):545-547. doi:
10.1002/cpt.2251. [PMID: 33882157] - Faiha M Al-Ardhi, Ladislav Novotny, Adel Alhunayan, Naser F Al-Tannak. Comparison of remdesivir and favipiravir - the anti-Covid-19 agents mimicking purine RNA constituents.
Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.
2022 Mar; 166(1):12-20. doi:
10.5507/bp.2021.063. [PMID: 34782799] - P Punyaratabandhu, S Vanitchpongphan. Favipiravir-induced cutaneous adverse reactions in patients infected with COVID-19.
Clinical and experimental dermatology.
2022 Mar; 47(3):573-577. doi:
10.1111/ced.14953. [PMID: 34592006] - Masao Sekimoto, Toru Imai, Shinji Hidaka, Nobutaka Chiba, Atsushi Sakurai, Mitsumasa Hata, Norikazu Kikuchi. Elevated INR in a COVID-19 patient after concomitant administration of favipiravir and warfarin: A case report.
Journal of clinical pharmacy and therapeutics.
2022 Mar; 47(3):407-410. doi:
10.1111/jcpt.13499. [PMID: 34339547] - Çağrı Turan, Nurcan Metin, Zeynep Utlu, Türkan Tuğba Yıldız, Selcen Caferoğlu Sakat. Evaluation of the frequency and intensity of favipiravir-associated yellow-green fluorescence in lunulae, hair, and face.
Journal of cosmetic dermatology.
2022 Mar; 21(3):1199-1207. doi:
10.1111/jocd.14189. [PMID: 33915020] - Paul Andrei Negru, Andrei-Flavius Radu, Cosmin Mihai Vesa, Tapan Behl, Mohamed M Abdel-Daim, Aurelia Cristina Nechifor, Laura Endres, Manuela Stoicescu, Bianca Pasca, Delia Mirela Tit, Simona Gabriela Bungau. Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2022 Mar; 147(?):112700. doi:
10.1016/j.biopha.2022.112700. [PMID: 35131656] - Emre Demir, Osman Sütcüoğlu, Beril Demir, Oktay Ünsal, Ozan Yazıcı. A possible interaction between favipiravir and methotrexate: Drug-induced hepatotoxicity in a patient with osteosarcoma.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
2022 Mar; 28(2):445-448. doi:
10.1177/10781552211031304. [PMID: 34255596] - Sivaraman Dhanasekaran, Muthamilan Chinnairusan, Leela Kagithakara Vajravelu. Letter in response to: Alamer A, Alrashed AA, Alfaifi M, et al. Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis. Curr Med Res Opin. 2021;19:1-13. DOI: 10.1080/03007995.2021.1920900.
Current medical research and opinion.
2022 03; 38(3):355-356. doi:
10.1080/03007995.2021.2020463. [PMID: 34933646] - Sinem Civriz Bozdağ, Güldane Cengiz Seval, İpek Yönal Hindilerden, Fehmi Hindilerden, Neslihan Andıç, Mustafa Baydar, Lale Aydın Kaynar, Selami Koçak Toprak, Hasan Sami Göksoy, Berrin Balık Aydın, Ufuk Demirci, Ferda Can, Vildan Özkocaman, Eren Gündüz, Zeynep Tuğba Güven, Zübeyde Nur Özkurt, Sinan Demircioğlu, Meral Beksaç, İdris İnce, Umut Yılmaz, Hilal Eroğlu Küçükdiler, Elgün Abishov, Boran Yavuz, Ünal Ataş, Yaşa Gül Mutlu, Volkan Baş, Fahir Özkalemkaş, Hava Üsküdar Teke, Vildan Gürsoy, Serhat Çelik, Rafiye Çiftçiler, Münci Yağcı, Pervin Topçuoğlu, Özcan Çeneli, Hamza Abbasov, Cem Selim, Muhlis Cem Ar, Orhan Kemal Yücel, Sevil Sadri, Canan Albayrak, Ahmet Muzaffer Demir, Nil Güler, Muzaffer Keklik, Hatice Terzi, Ali Doğan, Zeynep Arzu Yegin, Meltem Kurt Yüksel, Soğol Sadri, İrfan Yavaşoğlu, Hüseyin Saffet Beköz, Tekin Aksu, Senem Maral, Veysel Erol, Leylagül Kaynar, Osman İlhan, Ali Zahit Bolaman, Ömür Gökmen Sevindik, Arzu Akyay, Muhit Özcan, Günhan Gürman, Şule Ünal, Yasemin Yavuz, Reyhan Diz Küçükkaya, Güner Hayri Özsan. Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies.
Turkish journal of haematology : official journal of Turkish Society of Haematology.
2022 02; 39(1):43-54. doi:
10.4274/tjh.galenos.2021.2021.0287. [PMID: 34521187] - Konstantin P Katin, Alexey I Kochaev, Savas Kaya, Fadoua El-Hajjaji, Mikhail M Maslov. Ab Initio Insight into the Interaction of Metal-Decorated Fluorinated Carbon Fullerenes with Anti-COVID Drugs.
International journal of molecular sciences.
2022 Feb; 23(4):. doi:
10.3390/ijms23042345. [PMID: 35216462] - Chunchun Yao, Feng Xiang, Zhangyi Xu. Metal oxide nanocage as drug delivery systems for Favipiravir, as an effective drug for the treatment of COVID-19: a computational study.
Journal of molecular modeling.
2022 Feb; 28(3):64. doi:
10.1007/s00894-022-05054-6. [PMID: 35182223] - Takenao Koseki, Kazuki Nakajima, Hitoshi Iwasaki, Shigeki Yamada, Kazuo Takahashi, Yohei Doi, Tomohiro Mizuno. Baseline uric acid levels and steady-state favipiravir concentrations are associated with occurrence of hyperuricemia among COVID-19 patients.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
2022 Feb; 115(?):218-223. doi:
10.1016/j.ijid.2021.12.324. [PMID: 34910957] - Inas A Abdallah, Sherin F Hammad, Alaa Bedair, Ahmed H Elshafeey, Fotouh R Mansour. Determination of favipiravir in human plasma using homogeneous liquid-liquid microextraction followed by HPLC/UV.
Bioanalysis.
2022 Feb; 14(4):205-216. doi:
10.4155/bio-2021-0219. [PMID: 35001648] - Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan. Future of antivirals in COVID-19: The case of favipiravir.
International immunopharmacology.
2022 Feb; 103(?):108455. doi:
10.1016/j.intimp.2021.108455. [PMID: 34959188] - Ismail Celik, Meryem Erol, Zekeriya Duzgun. In silico evaluation of potential inhibitory activity of remdesivir, favipiravir, ribavirin and galidesivir active forms on SARS-CoV-2 RNA polymerase.
Molecular diversity.
2022 Feb; 26(1):279-292. doi:
10.1007/s11030-021-10215-5. [PMID: 33765239] - Burcu Kaya, Dilek Barutcu Atas, Elif Tukenmez Tigen, Ebru Asicioglu, Hakki Arikan, Serhan Tuglular, Arzu Velioglu. Favipiravir Use in Kidney Transplant Recipients with COVID-19: A Single-Center Experience.
Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation.
2022 02; 20(2):143-149. doi:
10.6002/ect.2021.0252. [PMID: 34981711] - Anandakrishnan Karthic, Veerbhan Kesarwani, Rahul Kunwar Singh, Pavan Kumar Yadav, Navaneet Chaturvedi, Pallavi Chauhan, Brijesh Singh Yadav, Sandeep Kumar Kushwaha. Computational Analysis Reveals Monomethylated Triazolopyrimidine as a Novel Inhibitor of SARS-CoV-2 RNA-Dependent RNA Polymerase (RdRp).
Molecules (Basel, Switzerland).
2022 Jan; 27(3):. doi:
10.3390/molecules27030801. [PMID: 35164069] - Inas A Abdallah, Sherin F Hammad, Alaa Bedair, Fotouh R Mansour. Menthol-assisted homogenous liquid-liquid microextraction for HPLC/UV determination of favipiravir as an antiviral for COVID-19 in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2022 Jan; 1189(?):123087. doi:
10.1016/j.jchromb.2021.123087. [PMID: 34974319] - Mojtaba Shohan, Roohangiz Nashibi, Mohammad-Reza Mahmoudian-Sani, Farhad Abolnezhadian, Mehri Ghafourian, Seyed Mohammad Alavi, Asaad Sharhani, Ali Khodadadi. The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial.
European journal of pharmacology.
2022 Jan; 914(?):174615. doi:
10.1016/j.ejphar.2021.174615. [PMID: 34863994] - Daisuke Yamada, Sachiko Ohde, Ryosuke Imai, Kengo Ikejima, Masaki Matsusako, Yasuyuki Kurihara. Visual classification of three computed tomography lung patterns to predict prognosis of COVID-19: a retrospective study.
BMC pulmonary medicine.
2022 Jan; 22(1):1. doi:
10.1186/s12890-021-01813-y. [PMID: 34980061] - Zeynep Tırmıkçıoğlu. Favipiravir exposure and pregnancy outcome of COVID-19 patients.
European journal of obstetrics, gynecology, and reproductive biology.
2022 Jan; 268(?):110-115. doi:
10.1016/j.ejogrb.2021.12.001. [PMID: 34902747] - Guzin Ozcifci, Tahacan Aydin, Zeynep Atli, Ilker Inanc Balkan, Fehmi Tabak, Mert Oztas, Yesim Ozguler, Serdal Ugurlu, Gulen Hatemi, Melike Melikoglu, Izzet Fresko, Vedat Hamuryudan, Emire Seyahi. The incidence, clinical characteristics, and outcome of COVID-19 in a prospectively followed cohort of patients with Behçet's syndrome.
Rheumatology international.
2022 01; 42(1):101-113. doi:
10.1007/s00296-021-05056-2. [PMID: 34825278] - Kazuhiro Itoh, Ippei Sakamaki, Tomoya Hirota, Hiromichi Iwasaki. Evaluation of minocycline combined with favipiravir therapy in coronavirus disease 2019 patients: A case-series study.
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
2022 Jan; 28(1):124-127. doi:
10.1016/j.jiac.2021.09.016. [PMID: 34627706] - Bhitta Surapat, Warissa Kobpetchyok, Sasisopin Kiertiburanakul, Vanlapa Arnuntasupakul. Use of Favipiravir for the Treatment of Coronavirus Disease 2019 in the Setting of Hospitel.
International journal of clinical practice.
2022; 2022(?):3098527. doi:
10.1155/2022/3098527. [PMID: 35685498] - Michael D Waters, Stafford Warren, Claude Hughes, Philip Lewis, Fengyu Zhang. Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: The special case of molnupiravir.
Environmental and molecular mutagenesis.
2022 01; 63(1):37-63. doi:
10.1002/em.22471. [PMID: 35023215] - Cemal Parlak, Özgür Alver, Cecil N M Ouma, Lydia Rhyman, Ponnadurai Ramasami. Can the Antivirals Remdesivir and Favipiravir Work Better Jointly? In Silico Insights.
Drug research.
2022 Jan; 72(1):34-40. doi:
10.1055/a-1585-1323. [PMID: 34535038] - Derya Bayırlı Turan, Mehtap Menteş, Yıldıran Özel, Kıvanç Şerefhanoğlu, Burcu Aydoğan, Neşe İbil, Füsun Güneşdoğdu, Hijran Mammadova Orucova, Cüneyt Saltürk, Hakan Çelik. The effect of favipiravir versus hydroxychloroquine on clinical and laboratory findings in COVID-19 in healthcare workers.
The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.
2022 Jan; 26(1):102328. doi:
10.1016/j.bjid.2022.102328. [PMID: 35139366] - Seyed MohammadReza Hashemian, Batoul Khoundabi, Ali Akbar Velayati. Comment on: Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia.
International immunopharmacology.
2022 01; 102(?):107693. doi:
10.1016/j.intimp.2021.107693. [PMID: 34217670] - Go Morikawa, Ken Kubota, Daichi Kondo, Yasuhisa Takanashi, Satoshi Minami, Tsunemichi Kinjo, Yukiko Moriiwa, Akio Yanagida, Katsuko Okazawa, Tomoshige Chiaki. Elevated blood favipiravir levels are inversely associated with ferritin levels and induce the elevation of uric acid levels in COVID-19 treatment: A retrospective single-center study.
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
2022 Jan; 28(1):73-77. doi:
10.1016/j.jiac.2021.10.011. [PMID: 34711508] - Elif Sargin Altunok, Celal Satici, Veysel Dinc, Sadettin Kamat, Mustafa Alkan, Mustafa Asim Demirkol, Ilkim Deniz Toprak, Muhammed Emin Kostek, Semih Yazla, Sinem Nihal Esatoglu. Comparison of demographic and clinical characteristics of hospitalized COVID-19 patients with severe/critical illness in the first wave versus the second wave.
Journal of medical virology.
2022 01; 94(1):291-297. doi:
10.1002/jmv.27319. [PMID: 34491575] - Subhradip Kundu, Debayan Sarkar. Synthetic Attempts Towards Eminent Anti-viral Candidates of SARS-CoV.
Mini reviews in medicinal chemistry.
2022; 22(2):232-247. doi:
10.2174/1389557521666210712205655. [PMID: 34254915] - Munise Daye, Pembe Oltulu. An AGEP case due to COVİD-19 or favipiravir or enoxaparin.
Journal of cosmetic dermatology.
2022 Jan; 21(1):13-15. doi:
10.1111/jocd.14622. [PMID: 34826196] - Manisha Saini, Minakshi Rana, Karun Bhatti, Rina Das, Dinesh Kumar Mehta, Ram Mohan Chidurala. Clinical Efficacy of Remdesivir and Favipiravir in the Treatment of COVID-19 Patients: Scenario so far.
Current drug research reviews.
2022; 14(1):11-19. doi:
10.2174/2589977513666210806122901. [PMID: 34365935] - Kübra Demir Önder, Ayşegül Seremet Keskin, Hande Berk, Derya Seyman, Nefise Öztoprak. Retrospective evaluation of seven different treatment protocols in hospitalized COVID-19 patients.
Turkish journal of medical sciences.
2021 12; 51(6):2835-2849. doi:
10.3906/sag-2106-114. [PMID: 34418000] - Şeyda Kayhan Ömeroğlu, Fehminaz Temel, Dilek Altun, Burak Öztop. Effects of hydroxychloroquine and favipiravir on clinical course in outpatients with COVID-19.
Turkish journal of medical sciences.
2021 12; 51(6):2827-2834. doi:
10.3906/sag-2101-146. [PMID: 34165273] - Rujittika Mungmunpuntipantip, Viroj Wiwanitkit. Hematological Malignancy Patients, COVID-19, and Favipiravir.
Turkish journal of haematology : official journal of Turkish Society of Haematology.
2021 12; 38(4):331-332. doi:
10.4274/tjh.galenos.2021.2021.0582. [PMID: 34792305] - Philippine Eloy, Roger Le Grand, Denis Malvy, Jérémie Guedj. Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One + zero equals two?.
EBioMedicine.
2021 Dec; 74(?):103663. doi:
10.1016/j.ebiom.2021.103663. [PMID: 34768087] - Selim Gök, Ömer Faruk Bahçecioğlu, Mefküre Durmuş, Zeynep Ülkü Gün, Yasemin Ersoy, Zeynep Ayfer Aytemur, Özkan Ulutaş. The safety profile of favipiravir in COVID-19 patients with severe renal impairment.
International journal of clinical practice.
2021 Dec; 75(12):e14938. doi:
10.1111/ijcp.14938. [PMID: 34605126] - Tanvi P Raiturcar, Chitralekha A Nayak. An unusual case of bluish discoloration of the cornea after favipiravir therapy for COVID-19.
Indian journal of ophthalmology.
2021 Dec; 69(12):3778-3779. doi:
10.4103/ijo.ijo_1023_21. [PMID: 34827050] - Batu Özlüşen, Şima Kozan, Rüştü Emre Akcan, Mekselina Kalender, Doğukan Yaprak, İbrahim Batuhan Peltek, Şiran Keske, Mehmet Gönen, Önder Ergönül. Effectiveness of favipiravir in COVID-19: a live systematic review.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology.
2021 Dec; 40(12):2575-2583. doi:
10.1007/s10096-021-04307-1. [PMID: 34347191] - Hiroyuki Fujii, Taisuke Tsuji, Mio Sugitani, Yosuke Matsumoto, Tatsuya Yuba, Shunya Tanaka, Yoshifumi Suga, Aosa Matsuyama, Shiho Goda, Ayaka Omura, Shinsuke Shiotsu, Chieko Takumi, Seiko Ono, Noriya Hiraoka. Prolonged persistence of SARS-CoV-2 infection during A+AVD therapy for classical Hodgkin's lymphoma: A case report.
Current problems in cancer.
2021 12; 45(6):100739. doi:
10.1016/j.currproblcancer.2021.100739. [PMID: 33810911] - Mohammad Mehmandoust, Yasamin Khoshnavaz, Mustafa Tuzen, Nevin Erk. Voltammetric sensor based on bimetallic nanocomposite for determination of favipiravir as an antiviral drug.
Mikrochimica acta.
2021 11; 188(12):434. doi:
10.1007/s00604-021-05107-2. [PMID: 34837114] - Abdullahi Tsanni. African scientists race to test COVID drugs - but face major hurdles.
Nature.
2021 11; 599(7883):25-27. doi:
10.1038/d41586-021-02995-5. [PMID: 34732862] - Yasemin Ozsurekci, Pembe Derin Oygar, Sibel Laçinel Gürlevik, Selman Kesici, Seza Ozen, Eda Didem Kurt Sukur, Bora Gülhan, Rezan Topaloglu, Benan Bayrakci, Ali Bülent Cengiz. Favipiravir use in children with COVID-19 and acute kidney injury: is it safe?.
Pediatric nephrology (Berlin, Germany).
2021 11; 36(11):3771-3776. doi:
10.1007/s00467-021-05111-x. [PMID: 34021797] - Ahmet Aktaş, Burak Tüzün, Rukiye Aslan, Koray Sayin, Hilmi Ataseven. New anti-viral drugs for the treatment of COVID-19 instead of favipiravir.
Journal of biomolecular structure & dynamics.
2021 11; 39(18):7263-7273. doi:
10.1080/07391102.2020.1806112. [PMID: 32783586] - Mehmet Erkan Kahraman, Fatih Yüksel, Yaşar Özbuğday. The relationship between Covid-19 and mucociliary clearance.
Acta oto-laryngologica.
2021 Nov; 141(11):989-993. doi:
10.1080/00016489.2021.1991592. [PMID: 34694199] - João Paulo Almirão de Jesus, Letícia Cristina Assis, Alexandre Alves de Castro, Elaine Fontes Ferreira da Cunha, Eugenie Nepovimova, Kamil Kuca, Teodorico de Castro Ramalho, Felipe de Almeida La Porta. Effect of drug metabolism in the treatment of SARS-CoV-2 from an entirely computational perspective.
Scientific reports.
2021 10; 11(1):19998. doi:
10.1038/s41598-021-99451-1. [PMID: 34620963] - Saghar Barati, Seyed MohammadReza Hashemian, Payam Tabarsi, Atefeh Abedini, Mahshid Ashrafzadeh, Sara Haseli, Zahra Abtahian, Sahar Yousefian, Alireza Dastan, Ali Sobhanian, Farzaneh Dastan. Combined Therapy of Ciclosporin Plus Favipiravir in the Management of Patients with Severe COVID-19, not Responding to Dexamethasone: A non-Controlled Prospective Trial.
International immunopharmacology.
2021 Oct; 99(?):108043. doi:
10.1016/j.intimp.2021.108043. [PMID: 34426105] - Chih-Cheng Lai, Chien-Ming Chao, Po-Ren Hsueh. Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials.
Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.
2021 Oct; 54(5):767-775. doi:
10.1016/j.jmii.2021.05.011. [PMID: 34253490] - Rana Abdelnabi, Caroline S Foo, Suzanne J F Kaptein, Xin Zhang, Thuc Nguyen Dan Do, Lana Langendries, Laura Vangeel, Judith Breuer, Juanita Pang, Rachel Williams, Valentijn Vergote, Elisabeth Heylen, Pieter Leyssen, Kai Dallmeier, Lotte Coelmont, Arnab K Chatterjee, Raf Mols, Patrick Augustijns, Steven De Jonghe, Dirk Jochmans, Birgit Weynand, Johan Neyts. The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model.
EBioMedicine.
2021 Oct; 72(?):103595. doi:
10.1016/j.ebiom.2021.103595. [PMID: 34571361] - Balint Gergely Szabo, Katalin Szidonia Lenart, Borisz Petrik, Zsofia Gaspar, Noemi Kiss-Dala, Janos Szlavik, Istvan Valyi-Nagy, Botond Lakatos. Favipiravir treatment does not influence disease progression among adult patients hospitalized with moderate-to-severe COVID-19: a prospective, sequential cohort study from Hungary.
GeroScience.
2021 10; 43(5):2205-2213. doi:
10.1007/s11357-021-00452-9. [PMID: 34476717] - Nida Bokharee, Yusra Habib Khan, Aisha Khokhar, Tauqeer Hussain Mallhi, Nasser Hadal Alotaibi, Maria Rasheed. Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials.
Expert review of anti-infective therapy.
2021 Oct; 19(10):1219-1244. doi:
10.1080/14787210.2021.1902805. [PMID: 33719819] - Kei Irie, Atsushi Nakagawa, Hirotoshi Fujita, Ryo Tamura, Masaaki Eto, Hiroaki Ikesue, Nobuyuki Muroi, Shoji Fukushima, Keisuke Tomii, Tohru Hashida. Population pharmacokinetics of favipiravir in patients with COVID-19.
CPT: pharmacometrics & systems pharmacology.
2021 10; 10(10):1161-1170. doi:
10.1002/psp4.12685. [PMID: 34292670] - Rujittika Mungmunpuntipantip, Viroj Wiwanitkit. Alectinib, COVID-19 and favipiravir.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
2021 10; 27(7):1810. doi:
10.1177/10781552211035823. [PMID: 34424078] - Thanawat Vongchaiudomchoke, Vittawin Sawangduan, Tosapon Sinpanee, Nipon Chalermphunchai, Kumtorn Lelamali, Kajohnsak Noppakun. Modification of immunosuppressive agents in a kidney transplant recipient with COVID-19 and acute kidney injury.
Journal of infection in developing countries.
2021 09; 15(9):1273-1276. doi:
10.3855/jidc.13176. [PMID: 34669595] - Weerawat Manosuthi, Somlerk Jeungsmarn, Pilailuk Okada, Pawita Suwanvattana, Warawan Wongboot, Unchana Thawornwan, Lantharita Charoenpong, Surasak Wiboonchutikul, Sumonmal Uttayamakul, Wannarat A Pongpirul, Apichat Wachirapan, Paijit Warachit. Nasopharyngeal SARS-CoV-2 Viral Load Response among COVID-19 Patients Receiving Favipiravir.
Japanese journal of infectious diseases.
2021 Sep; 74(5):416-420. doi:
10.7883/yoken.jjid.2020.827. [PMID: 33518623] - Yukiko Moriiwa, Go Morikawa, Katsuko Okazawa, Akio Yanagida. Optimization of Analytical Procedure for In-hospital Rapid Quantification of Serum Level of Favipiravir in the Pharmacological Treatment of COVID-19.
Analytical sciences : the international journal of the Japan Society for Analytical Chemistry.
2021 Sep; 37(9):1301-1304. doi:
10.2116/analsci.21n004. [PMID: 33612558] - Zainab Almoosa, Mustafa Saad, Samer Qara, Mahmoud Mustafa, Ali Mansour, Duaa Alshab, Jehad Alhashem, Sajida ALKhawajah, Saleh Alkhalifah, Mokhtar ALmarzooq, Mohammed ALzain, Neda'a Anshasi, Gasmelseed Ahmed, Abbas Al Mutair. Favipiravir versus standard of care in patients with severe COVID-19 infections: A retrospective comparative study.
Journal of infection and public health.
2021 Sep; 14(9):1247-1253. doi:
10.1016/j.jiph.2021.08.022. [PMID: 34464921] - Aditya K Padhi, Jagneshwar Dandapat, Prakash Saudagar, Vladimir N Uversky, Timir Tripathi. Interface-based design of the favipiravir-binding site in SARS-CoV-2 RNA-dependent RNA polymerase reveals mutations conferring resistance to chain termination.
FEBS letters.
2021 09; 595(18):2366-2382. doi:
10.1002/1873-3468.14182. [PMID: 34409597] - Masahiro Suzuki, Takumi Imai, Aki Sakurai, Satoshi Komoto, Tomihiko Ide, Chang Kweng Lim, Ayumi Shintani, Yohei Doi, Takayuki Murata. Virological and genomic analysis of SARS-CoV-2 from a favipiravir clinical trial cohort.
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
2021 Sep; 27(9):1350-1356. doi:
10.1016/j.jiac.2021.06.010. [PMID: 34176716] - Halit Çınarka, Gülşah Günlüoğlu, Mustafa Çörtük, Sibel Yurt, Murat Kıyık, Filiz Koşar, Elif Tanrıverdi, Melih Akay Arslan, Kürşad Nuri Baydili, Aysu Sinem Koç, Sedat Altın, Erdoğan Çetinkaya. The comparison of favipiravir and lopinavir/ritonavir combination in COVID-19 treatment.
Turkish journal of medical sciences.
2021 08; 51(4):1624-1630. doi:
10.3906/sag-2012-189. [PMID: 33726482] - Nicolas Dauby. Favipiravir as an Antiviral Agent in Coronavirus Disease 2019 (COVID-19): Same Script, Different Cast?.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2021 08; 73(3):e847-e848. doi:
10.1093/cid/ciaa1600. [PMID: 33075124] - Rahman Md Moshikur, Md Korban Ali, Rie Wakabayashi, Muhammad Moniruzzaman, Masahiro Goto. Favipiravir-Based Ionic Liquids as Potent Antiviral Drugs for Oral Delivery: Synthesis, Solubility, and Pharmacokinetic Evaluation.
Molecular pharmaceutics.
2021 08; 18(8):3108-3115. doi:
10.1021/acs.molpharmaceut.1c00324. [PMID: 34250805] - Yıldız Hayran, İlke Diren Albayrak, Devrim Tuba Öcalan, Akın Aktaş. Bilateral foot ulcers in a COVID-19 patient under favipiravir treatment.
Journal of cosmetic dermatology.
2021 Aug; 20(8):2390-2391. doi:
10.1111/jocd.14307. [PMID: 34146463] - Havva Kocayiğit, Gürkan Demir, Alper Karacan, Kezban Özmen Süner, Yakup Tomak, Selçuk Yaylacı, Hamad Dheir, Yasin Kalpakci, Ali Fuat Erdem. Effects on mortality of early vs late administration of convalescent plasma in the treatment of Covid-19.
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.
2021 Aug; 60(4):103148. doi:
10.1016/j.transci.2021.103148. [PMID: 33962885] - Gulsum Alkan, Hasibe Artac, Sadiye Kubra Tuter Oz, Melike Emiroglu. Management of COVID-19 pneumonia in a child with NEMO deficiency.
Immunologic research.
2021 08; 69(4):391-393. doi:
10.1007/s12026-021-09184-6. [PMID: 34061330] - Hong Zhao, Chi Zhang, Qi Zhu, Xianxiang Chen, Guilin Chen, Wenjin Sun, Zuohan Xiao, Weijun Du, Jing Yao, Guojun Li, Yanhua Ji, Niuniu Li, Yujin Jiang, Ying Wang, Qingjin Zeng, Wei Li, Beilei Gong, Xianyou Chang, Feng Zhu, Xiufeng Jiang, Jiawen Li, Zhao Wu, Yingxia Liu, Peng Peng, Guiqiang Wang. Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial.
International immunopharmacology.
2021 Aug; 97(?):107702. doi:
10.1016/j.intimp.2021.107702. [PMID: 33930706] - Shreshta Jain, Heidrun Potschka, P Prarthana Chandra, Manjari Tripathi, Divya Vohora. Management of COVID-19 in patients with seizures: Mechanisms of action of potential COVID-19 drug treatments and consideration for potential drug-drug interactions with anti-seizure medications.
Epilepsy research.
2021 08; 174(?):106675. doi:
10.1016/j.eplepsyres.2021.106675. [PMID: 34044300] - Duygu Gülseren, Başak Yalıcı-Armagan. Yellow-white fluorescence on the nails: A novel finding of Favipiravir used for the treatment of COVID-19.
Journal of cosmetic dermatology.
2021 Aug; 20(8):2392-2393. doi:
10.1111/jocd.14214. [PMID: 33978291] - Feride Yilmaz, Serkan Yasar, Meltem Caglar Tuncali, Serkan Akin. Complete response in a frail patient with high-grade B-cell lymphoma to only one cycle of R-CHOP or to prolonged COVID-19?.
Seminars in oncology.
2021 Aug; 48(4-6):279-282. doi:
10.1053/j.seminoncol.2021.11.001. [PMID: 34895738] - Mehmet Fatih Atak, Banu Farabi, Atiye Akbayrak, Mehmet Berati Kalelioğlu, Babar K Rao. Acute generalized exanthematous pustulosis following treatment with favipiravir in a patient with COVID-19 without hydroxychloroquine use: Report of the first case.
Journal of cosmetic dermatology.
2021 Aug; 20(8):2387-2389. doi:
10.1111/jocd.14304. [PMID: 34139069] - Seyed MohammadReza Hashemian, Tayebeh Farhadi, Ali Akbar Velayati. A review on favipiravir: the properties, function, and usefulness to treat COVID-19.
Expert review of anti-infective therapy.
2021 08; 19(8):1029-1037. doi:
10.1080/14787210.2021.1866545. [PMID: 33372567]
